stella
LUPUSJuly 2022Summary reviewed November 2026

New Antibody Treatment Reduced Cutaneous Lupus Skin Damage in Early Trial

An experimental antibody called litifilimab reduced skin disease activity in people with cutaneous lupus by up to one-third more than placebo over 16 weeks. The treatment targets immune cells involved in lupus. Larger studies are needed to confirm safety and long-term benefit.

What the trial was testing

The LILAC enrolled 264 patients with lupus. The study was sponsored by Biogen and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

Litifilimab reduced skin disease activity by up to one-third more than placebo.

The New England journal of medicine · 2022 · NCT02847598

These findings — that the highest-dose group improved 33 percentage points more than placebo on skin disease score. — were published in the The New England journal of medicine and represent the headline result of the study.

Researchers tracked outcomes across 264 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with lupus, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This early-stage study showed promise for a new lupus skin treatment, but it's not FDA-approved yet. The drug worked better than placebo, though some patients had infections like oral herpes. Ask your doctor about open trials or current approved lupus treatments.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.